A novel and efficient approach to discriminate between pre- and post-transcription HIV inhibitors

Molecular Pharmacology

Volumn 67, Issue 5, 2005, Pages 1574-1580

  Daelemans, Dirk ^a   Pannecouque, Christophe ^a   Pavlakis, George N ^b   Tabarrini, Oriana ^c   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GREEN FLUORESCENT PROTEIN; L 708906; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG; WM 12;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; FLUORESCENCE MICROSCOPY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HIV-1; HUMANS; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 17844364426     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.010249     Document Type: Article

References (37)

1. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, and Martin MA (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284-291.
2. Alexander L, Veazey RS, Czajak S, DeMaria M, Rosenzweig M, Lackner AA, Desrosiers RC, and Sasseville VG (1999) Recombinant simian immunodeficiency virus expressing green fluorescent protein identifies infected cells in rhesus monkeys. AIDS Res Hum Retroviruses 15:11-21.
3. Baba M, Okamoto M, Kawamura M, Makino M, Higashida T, Takashi T, Kimura Y, Ikeuchi T, Tetsuka T, and Okamoto T (1998) Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol Pharmacol 53:1097-1103.
4. Baba M, Okamoto M, Makino M, Kimura Y, Ikeuchi T, Sakaguchi T, and Okamoto T (1997) Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob Agents Chemother 41:1250-1255.
5. Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, and De Clercq E (1988) Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci USA 85:6132-6136.
6. De Clercq E (2002) Highlights in the development of new antiviral agents. Mini Rev Med Chem 2:163-175.
7. Feinberg MB, Baltimore D, and Frankel AD (1991) The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc Natl Acad Sci USA 88:4045-4049.
8. Felber BK, Hadzopoulou-Cladaras M, Cladaras C, Copeland T, and Pavlakis GN (1989) rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc Natl Acad Sci USA 88:1495-1499.
9. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, and McCarthy RE (1965) Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18:522-529.
10. Hadzopoulou-Cladaras M, Felber BK, Cladaras C, Athanassopoulos A, Tse A, and Pavlakis GN (1989) The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. J Virol 63:1265-1274.
11. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, et al. (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (Wash DC) 287:646-650.
12. Horwitz JP, Chua J, Noel M, and Darooge MA (1964) Nucleosides. IV. 1-(2-Deoxy-beta-D-lyxofuranosyl)-5-iodouracil. J Med Chem 15:385-386.
13. Kutsch O, Benveniste EN, Shaw GM, and Levy DN (2002) Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol 76:8776-8786.
14. Kutsch O, Levy DN, Bates PJ, Decker J, Kosloff BR, Shaw GM, Priebe W, and Benveniste EN (2004) Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription. Antimicrob Agents Chemother 48:1652-1663.
15. Lazzari S, de Felici A, Sobel H, and Bertagnolio S (2004) HIV drug resistance surveillance: summary of an April 2003 WHO consultation. Aids 18 (Suppl 3):S49-S53.
16. Lee AH, Han JM, and Sung YC (1997) Generation of the replication- competent human immunodeficiency virus type 1 which expresses a jellyfish green fluorescent protein. Biochem Biophys Res Commun 233:288-292.
17. Malim MH, Hauber J, Le SY, Maizel JV, and Cullen BR (1989) The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature (Lond) 338:254-257.
18. Mitsuya H, Looney DJ, Kuno S, Ueno R, Wong-Staal F, and Broder S (1988) Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science (Wash DC) 240:646-649.
19. Miyoshi I, Yoshimoto S, Kubonishi I, Taguchi H, Shiraishi Y, Ohtsuki Y, and Akagi T (1981) Transformation of normal human cord lymphocytes by co-cultivation with a lethally irradiated human T-cell line carrying type C virus particles. Gann 72:997-998.
20. Nakashima H, Pauwels R, Baba M, Schols D, Desmyter J, and De Clercq E (1989) Tetrazolium-based plaque assay for HIV-1 and HIV-2 and its use in the evaluation of antiviral compounds. J Virol Methods 26:319-329.
21. Okamoto H, Cujec TP, Okamoto M, Peterlin BM, Baba M, and Okamoto T (2000) Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37. Virology 272:402-408.
22. Page KA, Liegler T, and Feinberg MB (1997) Use of a green fluorescent protein as a marker for human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 13:1077-1081.
23. Palm GJ, Zdanov A, Gaitanaris GA, Stauber R, Pavlakis GN, and Wlodawer A (1997) The structural basis for spectral variations in green fluorescent protein. Nat Struct Biol 4:361-365.
24. Pannecouque C, Pluymers W, Van Maele B, Tetz V, Cherepanov P, De Clercq E, Witvrouw M, and Debyser Z (2002) New class of HIV integrase inhibitors that block viral replication in cell culture. Curr Biol 12:1169-1177.
25. Parolin C, Gatto B, Del Vecchio C, Pecere T, Tramontane E, Cecchetti V, Fravolini A, Masiero S, Palumbo M, and Palu G (2003) New anti-human immunodeficiency virus type 1 6-aminoquinolones: mechanism of action. Antimicrob Agents Chemother 47:889-896.
26. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, and Heykants J (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (Lond) 343:470-474.
27. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, and De Clercq E (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 20:309-321.
28. Popovic M, Sarngadharan MG, Read E, and Gallo RC (1984) Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (Wash DC) 224:497-500.
29. Richter S, Parolin C, Gatto B, Del Vecchio C, Brocca-Cofano E, Fravolini A, Palu G, and Palumbo M (2004a) Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative. Antimicrob Agents Chemother 48:1895-1899.
30. Richter S, Parolin C, Palumbo M, and Palu G (2004b) Antiviral properties of quinolone-based drugs. Curr Drug Targets Infect Disord 4:111-116.
31. Rosen CA, Sodroski JG, and Haseltine WA (1985) Location of cis-acting regulatory sequences in the human T-cell leukemia virus type I long terminal repeat. Proc Natl Acad Sci USA 82:6502-6506.
32. Salahuddin SZ, Markham PD, Wong-Staal F, Franchini G, Kalyanaraman VS, and Gallo RC (1983) Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. Virology 129:51-64.
33. Schols D, Pauwels R, Vanlangendonck F, Balzarini J, and De Clercq E (1988) A highly reliable, sensitive, flow cytometric/fluorometric assay for the evaluation of the anti-HIV activity of antiviral compounds in MT-4 cells. J Immunol Methods 114:27-32.
34. Stauber RH, Horie K, Carney P, Hudson EA, Tarasova NI, Gaitanaris GA, and Pavlakis GN (1998) Development and applications of enhanced green fluorescent protein mutants. Biotechniques 24:462- 6:468-471.
35. Tabarrini O, Stevens M, Cecchetti V, Sabatini S, Dell'uomo M, Manfroni G, Palumbo M, Pannecouque C, De Clercq E, and Fravolini A (2004) Structure modifications of 6-aminoquinolones with potent anti-HIV activity(1). J Med Chem 47:5567-5578.
36. Valentin A, Lu W, Rosati M, Schneider R, Albert J, Karlsson A, and Pavlakis GN (1998) Dual effect of interleukin 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression. Proc Natl Acad Sci USA 95:8886-8891.
37. Witvrouw M, Daelemans D, Pannecouque C, Neyts J, Andrei G, Snoeck R, Vandamme AM, Balzarini J, Desmyter J, Baba M, et al. (1998) Broad-spectrum antiviral activity and mechanism of antiviral action of the fluoroquinolone derivative K-12. Antivir Chem Chemother 9:403-411.